1 week Ago By ABMN Staff
Needham & Company LLC reaffirmed their buy rating on shares of Immunocore ( NASDAQ:IMCR – Free Report ) in a report released on Thursday morning, Benzinga reports. They currently have a $71.00 price target on the stock.
A number of other equities research analysts have also commented on the company. Mizuho decreased their price objective on Immunocore from $38.00 to $33.
00 and set a “neutral” rating for the company in a research report on Monday, April 7th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th.
Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock.
According to MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $65.18. Check Out Our Latest Stock Report on Immunocore Immunocore Stock Performance Insiders Place Their Bets In other Immunocore news, Director Bros.
Advisors Lp Baker bought 807,338 shares of the stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, with a total value of $23,994,085.
36. Following the acquisition, the director now directly owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20.
This represents a 60.40 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website .
Insiders own 9.10% of the company’s stock. Hedge Funds Weigh In On Immunocore Several large investors have recently added to or reduced their stakes in IMCR.
Groupama Asset Managment bought a new position in Immunocore during the fourth quarter worth about $17,700,000. Deep Track Capital LP bought a new position in shares of Immunocore during the 4th quarter worth approximately $15,322,000. Tang Capital Management LLC boosted its stake in Immunocore by 40.
7% in the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock valued at $45,890,000 after buying an additional 450,000 shares in the last quarter. Point72 Asset Management L.
P. bought a new stake in Immunocore in the fourth quarter valued at $11,897,000. Finally, T.
Rowe Price Investment Management Inc. raised its stake in Immunocore by 3.1% during the fourth quarter.
T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company’s stock worth $197,657,000 after acquiring an additional 200,373 shares in the last quarter.
Institutional investors and hedge funds own 84.50% of the company’s stock. About Immunocore ( Get Free Report ) Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. Featured Stories Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.
com's FREE daily email newsletter ..
